Johnson & Johnson Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Earnings Report - Johnson & Johnson is set to release its first-quarter earnings results on April 15, with analysts expecting earnings of $2.58 per share, a decrease from $2.71 per share in the same period last year [1] - The company is projected to report quarterly revenue of $21.57 billion, up from $21.38 billion a year earlier [1] Product Development - Protagonist Therapeutics announced new data for a pill treating moderate-to-severe plaque psoriasis, with the study conducted in adolescents and adults [2] - The data from the ICONIC program, involving icotrokinra (JNJ-2113), was developed through a partnership with Johnson & Johnson [2] Analyst Ratings - Raymond James analyst maintained an Outperform rating but reduced the price target from $165 to $162 [7] - Morgan Stanley analyst kept an Equal-Weight rating and raised the price target from $163 to $164 [7] - Guggenheim analyst reiterated a Neutral rating [7] - Barclays analyst maintained an Equal-Weight rating and increased the price target from $159 to $166 [7] - Stifel analyst maintained a Hold rating and cut the price target from $170 to $155 [7]